Evidence map›Paper›PMID 39853675›Full record

ArticleThe Journal of pathology2025

SMARCB1-deficient malignant melanocytic uveal tumours: a new neural crest-derived tumour entity with SMARCB1-related germline predisposition.

Joanna Cyrta, Julien Masliah-Planchon, Owen Hoare, Riwan Brillet, Mamy Andrianteranagna, Pierre Sohier, Liesbeth Cardoen, Yassine Bouchoucha, Mathilde Filser, Andreia Goncalves and 13 more

Abstract readCase Reports
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Joanna CyrtaDepartment of Pathology, Institut Curie, PSL Research University, Paris, France.ORCID 0000-0002-0216-5330
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Owen HoareSIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.
Riwan BrilletDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Mamy AndrianteranagnaSIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.
Pierre SohierDepartment of Pathology, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, France.
Liesbeth CardoenDepartment of Imaging, Institut Curie, Paris, France.
Yassine BouchouchaSIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.ORCID 0000-0002-9965-6573
Mathilde FilserDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Andreia GoncalvesDepartment of Pathology, Institut Curie, PSL Research University, Paris, France.
Martial CalyDepartment of Pathology, Institut Curie, PSL Research University, Paris, France.
Paul FréneauxDepartment of Pathology, Institut Curie, PSL Research University, Paris, France.
Kalliopi StefanakiDepartment of Pathology, Agia Sofia Children's Hospital, Athens, Greece.
Maria PefkianakiOcular Oncology Center, MITERA Hospital, Athens, Greece.
Maria MoschoviPediatric Hematology/Oncology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Children's Hospital, Athens, Greece.
Alexandre MatetDepartment of Ocular Oncology, Institut Curie, Université Paris Cité, Paris, France.
Nathalie CassouxDepartment of Ocular Oncology, Institut Curie, Université Paris Cité, Paris, France.
Livia Lumbroso-Le RouicDepartment of Ocular Oncology, Institut Curie, Université Paris Cité, Paris, France.
Marion Gauthier-VillarsDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Marc-Henri SternDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Anne Vincent-SalomonDepartment of Pathology, Institut Curie, PSL Research University, Paris, France.
Manuel RodriguesINSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, PSL Research University, Paris, France.
Franck BourdeautSIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.ORCID 0000-0001-9489-6781

Funding

Agence Nationale de la Recherche ANR-10-EQPX-03Agence Nationale de la Recherche ANR-10-INBS-09-08INSERM
6 · The paper itself

Abstract

Rhabdoid tumours (RT) are an aggressive malignancy affecting <2-year-old infants, characterised by biallelic loss-of-function alterations in SWI/SNF-related BAF chromatin remodelling complex subunit B1 (SMARCB1) in nearly all cases. Germline SMARCB1 alterations are found in ~30% of patients and define the RT Predisposition Syndrome type 1 (RTPS1). Uveal melanoma (UVM), the most common primary intraocular cancer in adults, does not harbour SMARCB1 alterations. We report two cases of a previously undescribed intraocular malignancy that shared some features with UVM and RT, but was also distinct from these entities. Both female patients, aged 23 and 14 years, underwent enucleation, and the tumours were subjected to comprehensive genomic, DNA methylation, and transcriptomic profiling. Pathological examination showed large, amelanotic intraocular tumours with epithelioid features, expressing melanocytic markers [S100P, SOX10, Melan-A, PMEL (HMB45), TYR] as seen using immunohistochemistry (IHC), but with little or no melanin production. Both tumours harboured biallelic loss-of-function SMARCB1 alterations, associated with loss of SMARCB1 (BAF47/INI1) expression on IHC. Their genomic profiles were atypical both for UVM and for RT, and no pathogenic variants were found in other genes tested, including those recurrently altered in UVM. In both patients, a germline SMARCB1 variant was found. However, there was no relevant family history of cancer. Transcriptome and methylome profiling suggested that these tumours were distinct from RT, UVM, and skin melanomas. RNAseq confirmed expression of early and late genes related to melanocytic differentiation. The first patient died of metastatic disease 16 months after diagnosis, the second was disease-free 10 months after completion of treatment. In summary, we report two cases of a previously undescribed, aggressive SMARCB1-deficient intraocular malignancy with melanocytic differentiation, which occurs in young patients, is distinct from UVM and RT, and expands the RTPS1 spectrum. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Genetic Predisposition to DiseaseGerm-Line MutationMelanomaSMARCB1 ProteinUveal NeoplasmsAdolescentBiomarkers, TumorDNA MethylationFemaleHumansNeural CrestRhabdoid TumorYoung AdultBiomarkers, TumorSMARCB1 ProteinSMARCB1 protein, humanBAF47eye cancergenomicsINI1neural crestrhabdoid tumourRTPS1SMARCB1SWI/SNFuveal melanoma

Identifiers

PMID39853675
PMCPMC11794973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.